FDA Approves Dysport for Treatment of Lower Limb Spasticity In Adults

The U.S. Food and Drug Administration (FDA) has expanded approval of Dysport (abobotulinumtoxinA) for treatment of spasticity in adults, a condition that affects many people in the United States, including multiple sclerosis patients. The decision was based on Dysport’s supplemental Biologics License Application (sBLA) in lower limb spasticity and Phase 3 clinical study results.

This treatment, marketed by Ipsen, was the first and only botulinum toxin approved by the FDA in July 2016 for the treatment of lower limb spasticity in pediatric patients aged 2 and older.

“Adult patients who have developed spasticity as a result of a stroke, Multiple Sclerosis, Cerebral Palsy, spinal cord injury, or traumatic brain injury now have another option when seeking treatment that helps reduce the effects of the increased muscle tone in their lower extremities,” Alexandre Lebeaut, MD, Ipsen’s executive vice president of research and development and chief scientific officer, said in a ... read more at: https://multiplesclerosisnewstoday.com/2017/06/19/ms-lower-limb-spasticity-treatment-dysport-approved-by-fda-for-adults/

Leave a Reply